By Colin Kellaher
Medical-technology company Teleflex said it plans to spin off its urology, acute-care and OEM businesses into an independent, publicly traded company.
Teleflex on Thursday said the remaining company, consisting of its vascular access, interventional and surgical businesses, will focus on high-growth, primarily hospital-focused emergent end markets.
The Wayne, Pa., company said it expect to complete the tax-free spinoff by mid-2026.
Teleflex said it expects the remaining company, with pro-forma 2024 revenue of about $2.1 billion, to generate constant-currency revenue growth topping 6%. The company said the spinoff had about $1.4 billion in revenue in 2024.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2025 07:42 ET (12:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。